Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 15/20 | 0.64 |
| ▸ | MAPK13 | O15264 | 10/20 | 0.64 |
| ▸ | MAPK12 | P53778 | 10/20 | 0.64 |
| ▸ | MAPK11 | Q15759 | 10/20 | 0.64 |
| ▸ | EGFR | P00533 | 4/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.49 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.48 |
| ▸ | PARP1 | P09874 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4585385 | 0.80 | ALOX5 (0.62) | MAPK14MAPK13MAPK12MAPK11EGFR | |
| SCHEMBL4584037 | 0.79 | MAPK14 (0.61) | MAPK14MAPK13MAPK12MAPK11EGFR | |
| SCHEMBL4584803 | 0.79 | MAPK14 (0.62) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL4586000 | 0.79 | MAPK14 (0.61) | MAPK14MAPK13MAPK12MAPK11EGFR | |
| SCHEMBL4592945 | 0.78 | MAPK13 (1.00) | MAPK14MAPK13MAPK12MAPK11ACVR1 | |
| SCHEMBL4584122 | 0.78 | MAPK14 (0.50) | MAPK14MAPK13MAPK12MAPK11EGFR | |
| SCHEMBL4585395 | 0.77 | ALOX5 (0.61) | MAPK14MAPK13MAPK12MAPK11EGFR | |
| SCHEMBL4584431 | 0.77 | MAPK14 (0.64) | MAPK14MAPK13MAPK12MAPK11EGFR | |
| SCHEMBL4584585 | 0.76 | MAPK14 (0.52) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL8860476 | 0.76 | MAPK13 (0.86) | MAPK14MAPK13MAPK12MAPK11ACVR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1539121-A4 | METHODS OF PROMOTING OSTEOGENESIS | SCIOS INC (US) | 2008-08-13 | — | — | EP | disclosed |
| EP-1583535-A4 | METHODS FOR TREATING DIABETES | SCIOS INC (US) | 2008-03-19 | — | — | EP | disclosed |
| EP-1583535-A2 | METHODS FOR TREATING DIABETES | SCIOS INC. (US) | 2005-10-12 | — | — | EP | disclosed |
| EP-1539121-A2 | METHODS OF PROMOTING OSTEOGENESIS | SCIOS INC. (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004019873-A9 | METHODS OF PROMOTING OSTEOGENESIS | SCIOS INC (US) | 2004-06-24 | — | — | WO | disclosed |
| WO-2004053107-A2 | METHODS FOR TREATING DIABETES | SCIOS INC. (US) | 2004-06-24 | — | — | WO | disclosed |
| WO-2004019873-A2 | METHODS OF PROMOTING OSTEOGENESIS | SCIOS INC. (US) | 2004-03-11 | — | — | WO | disclosed |
| US-5670527-A | CYTOKINE INHIBITORS USEFUL IN TREATING ASTHMA, OSTEOPOROSIS, ARTHRITIS, INFLAMMATION, SEPSIS, CARDIOVASCULAR DISORDERS, DIABETES, MULTIPLE SCLEROSIS, SKIN DISORDERS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-09-23 | — | — | US | disclosed |